Regenesis Biomedical- Utilizing Energy to Reduce Pain
Regenesis Biomedical’s Provant Therapy System is FDA approved for the palliative treatment of post-operative pain and edema in superficial soft tissue. Post surgery, many tissues may be moved around or inflamed, but Provant helps reduce the pain by inducing endogenous opioids. This prescription only device exposes tissue to electromagnetic energy using an optimized energy pulse.
Read more »
NeoStem Discovering the Power of Stem Cell Technology in Wound Care
Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
Read more »
NanoViricides’ drug FluCide found safe in small animal studies
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides is also developing drugs against HIV/AIDS (HivCide™-I), Dengue (DengueCide™-I), and External Eye Viral disease (EKC-Cide™-I), amongst other viral diseases.
Read more »
Soft Tissue Regeneration’s First Bioengineered Matrix Successfully Implanted in 7 Patients
STR has started a clinical trial in Europe for its ACL device and has successfully implanted the device in 7 patients as of October 2013. Their device utilizes a synthetic scaffold that regenerates the entire ligament tissue resulting in better chances of full recovery.
Read more »
Profound Medical’s Device on Fast Track for Commercialization
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.
Read more »
7th Annual OneMedForum to address ‘train wreck’ called US healthcare
NEW YORK, Oct. 15, 2013 – OneMedForum announced today that a major theme of its 7th annual healthcare investing conference will be to provide investors with an outlook about how the healthcare system will function post-Obamacare. Moreover, it will also address the new financing opportunities created by the JOBS Act and feature innovatively growing companies that are best positioned to succeed in this new environment.
Read more »Orexigen: Anti-Obesity Drug Attempting to Enter Multiple Markets
Orexigen Therapeutics is a biopharmaceutical company that focuses its attention on the treatment of one of the most common diseases in existence today, obesity.
Read more »
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
Read more »